MedTrace Logo

A Phase 1 Study of the Safety and Tolerability of CTX-10726

NCT07419841 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Conditions

  • Gastroesophageal Cancer (GC)
  • Hepatocellular Carcinoma (HCC)
  • Endometrial Cancer
  • Renal Cell Carcinoma (RCC)

Interventions

DRUG

CTX-10726

Intravenous (IV) infusion (0.3-10.0mg/kg) every two weeks.

Sponsors & Collaborators

  • Compass Therapeutics

    lead INDUSTRY

Principal Investigators

  • Cynthia Sirard, MD · Compass Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-04-01
Completion
2028-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07419841 on ClinicalTrials.gov